Edition:
United Kingdom

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

14.08USD
18 Sep 2018
Change (% chg)

$0.94 (+7.15%)
Prev Close
$13.14
Open
$13.12
Day's High
$14.15
Day's Low
$13.12
Volume
82,336
Avg. Vol
81,336
52-wk High
$17.90
52-wk Low
$4.93

Latest Key Developments (Source: Significant Developments)

Ra Pharmaceuticals Q2 Loss Per Share $0.49
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND ANNOUNCES EARLY COMPLETION OF ENROLLMENT IN GMG PHASE 2 PROGRAM.Q2 LOSS PER SHARE $0.49.Q2 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.COMPANY EXPECTS THAT ITS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2019.AS OF JUNE 30, 2018, RA PHARMA REPORTED TOTAL CASH AND CASH EQUIVALENTS OF $95.1 MILLION.TOP-LINE DATA FOR PHASE 2 TRIAL OF RA101495 SC NOW EXPECTED AROUND YEAR-END 2018.  Full Article

Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS.RA PHARMACEUTICALS INC - TOPLINE DATA FROM SECOND CLINICAL INDICATION OF RA101495 SC EXPECTED FIRST HALF OF 2019.  Full Article

Ra Pharmaceuticals posts Q3 loss of $0.68 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Ra Pharmaceuticals Inc :Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.68.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.As of September 30, 2017, Ra Pharma reported total cash and equivalents of $84.1 million​.Company expects that its cash and cash equivalents will be sufficient to fund operations through end of 2018​.  Full Article

Ra Pharmaceuticals files for mixed shelf offering of up to $250 million
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Ra Pharmaceuticals Inc :Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​.  Full Article

Lightstone Ventures LP reports 5.9 pct passive stake in Ra Pharmaceuticals Inc as on Dec 31, 2016
Tuesday, 14 Feb 2017 

Ra Pharmaceuticals Inc :Lightstone Ventures L.P. reports 5.9 percent passive stake in ra pharmaceuticals inc as on December 31, 2016 - SEC filing.  Full Article

BRIEF-Ra Pharma - Entered Sales Agreement With Stifel Pursuant To Which Co May Sell, Up To $50 Mln Of Shares Of Common Stock

* RA PHARMA - ENTERED SALES AGREEMENT WITH STIFEL PURSUANT TO WHICH CO MAY SELL, UP TO $50 MILLION OF SHARES OF COMMON STOCK, THROUGH STIFEL AS SALES AGENT Source text: (https://bit.ly/2G0vejI) Further company coverage: